September 5, 2017 / 10:21 AM / 20 days ago

BRIEF-Biocryst announces positive results from mid-stage HAE trial

Sept 5 (Reuters) - Biocryst Pharmaceuticals Inc

* Biocryst announces positive results from its Apex-1 Phase 2 trial in HAE

* Biocryst Pharmaceuticals Inc - ‍FDA and EMA meetings planned for Q4 2017 to finalize phase​

* Biocryst Pharmaceuticals Inc - in Apex Phase 2 trial, ‍73% reduction in overall attack frequency at 125mg dose (p<0.001)​

* Biocryst Pharmaceuticals Inc - ‍goal is to start Phase 3 efficacy and long-term safety trials in Q1 of 2018​

* Biocryst Pharma- ‍125 mg dose level showed statistically significant,similar benefit for all attacks, also when split into abdominal attacks,peripheral attacks​

* Biocryst Pharmaceuticals Inc - ‍intends to meet FDA, EMA during Q4 2017 to finalize Phase 3 program required to support NDA, MAA submissions​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below